Reyataz label
Atazanavir AUC(tau) increased 43%
Ledipasvir AUC(tau) increased 134%, Cmax increased 75%
Potentially increased ledipasvir adverse effects. Potentially increased tenofovir disoproxil fumarate adverse effects if coadministered with protease inhibitor and ledipasvir.
If coadministering, monitor for tenofovir disoproxil fumarate toxicity if used in the regimen.

